GSK acquires Aiolos Bio for $1.4bn to boost respiratory portfolio
10 Jan 2024
Drug ApprovalAcquisitionPhase 2
Preview
Source: Pharmaceutical Technology
GSK has agreed to acquire the asthma drug specialist Aiolos Bio for a deal worth up to $1.4bn, as it aims to strengthen its respiratory and inflammatory asset pipeline.
GSK will pay $1bn upfront to acquire the Anglo-American biopharma, with a further $400m on the line in success-based regulatory milestones, according to a 9 January press release. The companies did not reveal when the deal is expected to close.
GSK’s acquisition will give the company access to Aiolos’ AIO-001, a monoclonal antibody that is ready to start Phase II trials for the treatment of asthma in adults. The asset targets thymic stromal lymphopoietin which, according to the companies, is a driver of inflammation in diseases such as asthma. GSK will also assess the drug’s potential use in the treatment of chronic rhinosinusitis with nasal polyps.
AIO-001 has the potential to be administered every six months – far less frequently than current treatments used to manage symptoms of asthma. US Food and Drug Administration (FDA)-approved Xolair (omalizumab) developed by Novartis, for example, is administered every two to four weeks. AstraZeneca’s Tezspire (tezepelumab-ekko), FDA-approved for severe asthma in adults, is administered monthly.
GSK’s chief scientific officer Tim Wood said AIO-001 could expand the reach of the company’s respiratory biologics portfolio, highlighting “the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed”.
In October 2023, Aiolos launched in a $245m Series A round. The company licensed AIO-001 from Jiangsu Hengrui Pharmaceuticals for use outside of Greater China. The Chinese pharma company is also in line for milestone and royalty-based payments from GSK.
GSK is the fourth big pharma to make moves amid the J P Morgan Healthcare Conference currently being held in San Francisco, US. Johnson & Johnson spent $2bn to acquire Ambrx, boosting its oncology portfolio. MSD also strengthened its cancer assets by acquiring T-cell engager specialist Harpoon Therapeutics for $680m. Novartis, having already spent $250m to acquire Calypso Biotech, is reportedly in advanced talks to acquire Cytokinetics for $10bn, according to Reuters.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.